We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Vigorous Mixing May Effect Blood Results

By LabMedica International staff writers
Posted on 21 Feb 2013
Print article
The effect of tube mixing techniques on the quality of diagnostic blood specimens collected in vacuum tube systems by venipuncture has been evaluated.

The accurate mixing of blood in tubes with anticoagulant- or clot activator additives is essential for their effectiveness and may influence the reliability of test results and thereby affect the diagnostic outcome, the follow-up, and the therapeutic management of patients.

Clinical biochemists at the University of Verona (Italy) collected blood from 100 volunteers for routine coagulation, immunochemistry, and hematological testing from April 1, 2012, to May 1, 2012. The blood was put into six vacuum tubes: two 3.6 mL vacuum tubes containing 0.4 mL of buffered sodium citrate; two 3.5 mL vacuum tubes with clot activator and gel separator; and two 3.0 mL vacuum tubes containing dipotassium ethylenediaminetetraacetic acid (K2EDTA). All vacuum tubes, each of one additive type were processed through two different procedures.

The standard procedure was blood specimens in K2EDTA- or sodium citrate-vacuum tubes were gently inverted five times whereas the specimens in tubes with clot activator and gel separator were gently inverted ten times. The second procedure consisted of all the blood specimens were shaken up vigorously during three to five seconds independently of the additive type inside the tubes.

Routine hematology, clinical chemistry, and immunochemistry and coagulation tests were performed. The results of the investigation for all the parameters showed that no significant differences were detected between the standard procedures versus the vigorous mix. Only a visual alteration with the presence of foam on the top was shown by all the tubes mixed vigorously before centrifugation. The serum tubes from vigorous mixing procedure shows a “blood ring” on the tube top after stopper removal.

The vacuum tubes used were manufactured by Terumo Europe (Heverlee, Belgium). The authors concluded that primary blood tubes vigorous mixing does not promote laboratory variability and suggest that similar evaluation should be done using other brands of vacuum tubes by each laboratory manager. The study was published in the February 2013 issue of the journal Clinical Biochemistry.

Related Links:

University of Verona
Terumo Europe



Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Piezoelectric Micropump
Disc Pump
New
Centromere B Assay
Centromere B Test

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.